Finsgate
5-7 Cranwood Street
London EC1V 9EE
United Kingdom
May 8, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attention: Nicholas OLeary
Re: | Renalytix plc |
Registration Statement on Form F-3
Filed on May 2, 2023
File No. 333-271579
Acceleration Request
Requested Date: May 10, 2023
Requested Time: 4:00 p.m. Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form F-3 (File No. 333-271579) (the Registration Statement) to become effective at 4:00 p.m. Eastern Time on May 10, 2023, or as soon thereafter as is practicable.
Once the Registration Statement has been declared effective, please orally confirm that event with Katie Kazem of Cooley LLP, counsel to the Registrant, at (703) 456-8043.
[Signature page follows]
1
Very truly yours,
RENALYTIX PLC
By: | /s/ James McCullough | |
James McCullough | ||
Chief Executive Officer | ||
cc: | O. James Sterling, Renalytix plc | |
Marc Recht, Cooley LLP | ||
Madison Jones, Cooley LLP | ||
Katie Kazem, Cooley LLP |
2